IP Library › Granted Patent US 12,215,087
Granted Patent B2
US 12,215,087 · App. 18/353,422 · Granted Feb 4, 2025

Inhibitors of NLRP3 inflammasome

Inventors: George Hartman (Lansdale, PA); Paul Humphries (Menlo Park, CA); Kevin Edward Leif Wilhelmsen (Albany, CA)
Assignee: BioAge Labs, Inc.
C07D231/56C07D235/06C07D401/12C07D403/12C07D405/12C07D413/12C07D417/12C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,215,087
App. No.
18/353,422
Granted
Feb 4, 2025
Kind
B2
Abstract

The present disclosure relates to compounds that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including hearing loss and other diseases associated with aging.

Claims (9)

1. A compound that is

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

3. A compound that is

or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition comprising the compound of claim 3 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

5. A compound that is

or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition comprising the compound of claim 5 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2024
From: HARTMAN, GEORGE; HUMPHRIES, PAUL; WILHELMSEN, KEVIN EDWARD LEIF
To: BIOAGE LABS, INC.
Reel/Frame 068546/0304 →
Continuity (4)
Continuation 17701856 · Mar 23, 2022
Provisional Application 63164780 · Mar 23, 2021
Provisional Application 63219538 · Jul 8, 2021
Related Publication 20240067610A1 · Feb 29, 2024
References Cited (36)
US 11708334B2 · Hartman · 2023 [cited by examiner]
US 11787805B2 · Hartman · 2023 [cited by examiner]
US 20220324812A1 · Hartman et al. · 2022 [cited by applicant]
US 20230365507A1 · Hartman · 2023 [cited by examiner]
US 20240067648A1 · Hartman · 2024 [cited by examiner]
US 20240116933A1 · Hartman · 2024 [cited by examiner]
CN 111329993A · 2020 [cited by applicant]
EP 2269990A1 · 2011 [cited by applicant]
EP 3660003A1 · 2020 [cited by applicant]
WO WO2004099143A1 · 2004 [cited by applicant]
WO WO2008006561A1 · 2008 [cited by applicant]
WO WO2012101453A1 · 2012 [cited by applicant]
WO WO2013126856A1 · 2013 [cited by applicant]
WO WO2016081290A1 · 2016 [cited by applicant]
WO WO2019001416A1 · 2019 [cited by applicant]
WO WO2019193342A1 · 2019 [cited by applicant]
WO WO2020097389A1 · 2020 [cited by applicant]
Fischer et al., “Age-Dependent Changes in the Cochlea”, [cited by applicant]
Franceshi et al., “Inflamm-aging: An Evolutionary Perspective on Immunosenescence”, [cited by applicant]
Hubbard et al., “Frailty, inflammation and the elderly” [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/021461, mailed Jun. 14, 2022, 15 pages. [cited by applicant]
Kang et al., “Synthesis and structure-activity relationships of novel fused ring analogues of Q203 as antitubercular agents”, [cited by applicant]
Le Prell et al., “Noise-induced hearing loss and its prevention: current issues in mammalian hearing” [cited by applicant]
Montalvao et al., “Synthesis and Biological Evaluation of 2-Aminobenzothiazole and Benzimidazole Analogs Based on the Clathrodin Structure”, [cited by applicant]
Nakanishi et al., “NLRP3 mutation and cochlear autoinflammation cause syndromic and nonsyndromic hearing loss DFNA34 responsive to anakinra therapy”, [cited by applicant]
Nakanishi et al., “Genetic Hearing Loss Associated With Autoinflammation”, [cited by applicant]
Schwaid et al., “Strategies for Targeting the NLRP3 Inflammasome in the Clinical and Preclinical Space”, [cited by applicant]
Yao et al., “Inflammation and Immune Systems Alterations in Frailty”, [cited by applicant]
Yee et al., “Zika virus infection causes widespread damage to the inner ear”, [cited by applicant]
Zahid et al., “Pharmacological Inhibitors of the MLRP3 Inflammasome”, [cited by applicant]
U.S. Appl. No. 17/701,856 / 2022-0324812 A1 / U.S. Pat. No. 11,702,391, filed Mar. 23, 2022 / Oct. 13, 2022 / Jul. 18, 2023, George Hartman. [cited by applicant]
U.S. Appl. No. 17/930,895 / 2023-0051130 A1 / U.S. Pat. No. 11,708,334, filed Sep. 9, 2022 / Feb. 16, 2023 / Jul. 25, 2023, George Harman. [cited by applicant]
U.S. Appl. No. 18/323,939, filed May 25, 2023, George Hartman. [cited by applicant]
U.S. Appl. No. 18/353,410, filed Jul. 17, 2023, George Hartman. [cited by applicant]
U.S. Appl. No. 18/353,422, filed Jul. 17, 2023, George Hartman. [cited by applicant]
U.S. Appl. No. 18/353,370, filed Jul. 17, 2023, George Hartman. [cited by applicant]
Cited By (1)
US 12,509,459